Jan 26, 2015
San Diego, CA (PRWEB) January 23, 2015
Favorable research study results for Arthur Andrew Medical’s dietary supplement, Neprinol, were presented at the Scripps 12th Annual Natural Supplements Conference. The scientific poster entry won First Place at the distinguished event.
Arthur Andrew Medical’s dietary supplement, Neprinol, was recently the center of an open-label study geared towards determining its ability to impact several cardiovascular function markers. The study results were presented at the Scripps 12th Annual Natural Supplements Conference. The research findings were presented as a scientific poster entry which won First Place at the distinguished event.
“The Effects of a Proprietary Blend of Natural Enzymes on Cardiovascular Health: An Open-Label Study,” exhibited positive results for Neprinol, a proprietary blend of natural enzymes designed to improve cardiovascular health by improving blood composition and blood vessel function, and further support healthy glucose tolerance and lipid levels.
The objective of the study was to demonstrate the effect of the investigational product’s systemic enzymes, including serrapeptase, nattokinase, protease, lipase, bromelain, papain, rutin and amla, on an array of cardiovascular function markers. Systemic enzymes are similar to digestive enzymes, but primarily target the bloodstream rather than the gastrointestinal tract.
The 12-week open-label study revealed statistically significant results supporting the product claims. An EndoPAT test was used to clinically assess vessel function during the course of the trial.
“The Neprinol study product significantly improved both systolic and diastolic blood viscosity at both 6 and 12 weeks. Reductions in blood viscosity may be associated with improved blood flow and are a sign of overall cardiovascular wellness,” explained Dr. Jay Udani. “As this was a healthy population with elevated inflammatory markers at baseline, improvements in cardiovascular risk, such as reductions in blood viscosity, may be helpful in reducing the overall risk profile of these individuals.”
The study also concluded that Arthur Andrew Medical’s proprietary blend of natural enzymes effectively supports healthy blood sugar levels in healthy overweight or obese individuals with slightly elevated levels of inflammation and impaired glucose tolerance. These results indicate that Neprinol may improve overall cardiovascular function and health in a non-diseased population.
“Our study’s outcome was very exciting and we are truly honored to have been awarded First Place at this prestigious event, said Aaron Gillam, President, Arthur Andrew Medical. “The recognition by Scripps further exemplifies how profound our study findings truly were.”
The Scripps conference, held annually in San Diego, utilizing peer review, selects the most relevant abstracts and scientific posters that present a concise, clinically relevant overview of their evidence-based research. Award winners were announced Jan. 18.
About Arthur Andrew Medical
Arthur Andrew Medical is a leading and pioneering manufacturer of enzyme and probiotic based dietary supplements. Founded in 2004 by Justin Andrew Marsh, Arthur Andrew leads the way in developing and launching new and novel products for the natural support of many common ailments. They also endeavor to provide the utmost in product support and education, including clinical research and case studies.
Arthur Andrew Medical is dedicated to conducting research and clinical applications with dietary supplements for the advancement of natural health alternatives. Arthur Andrew utilizes only the best products that nature can offer, and ensures that they are supported by education and innovation. They strive to only offer products that are hypo-allergenic and free of pthalates, preservatives, coatings, binders, artificial flavors, artificial sweeteners and colors, fragrances and excipients.
Learn more about Arthur Andrew by visiting http://www.arthurandrew.com.